TC Biopharm Raises $500K in Private Placement

TL;DR

TC Biopharm closed a $500K private placement of shares and warrants to accredited investors.

AI Summary

On March 12, 2024, TC Biopharm (Holdings) plc announced the closing of a private placement of 1,000,000 ordinary shares at a price of $0.50 per share, raising gross proceeds of $500,000. The company also issued warrants to purchase an additional 1,000,000 ordinary shares at an exercise price of $0.75 per share. These securities were offered to accredited investors.

Why It Matters

This capital raise provides TC Biopharm with funds that can be used for its ongoing operations and development of its cancer therapies.

Risk Assessment

Risk Level: medium — The company is raising capital through a private placement, which can indicate a need for funding and potential dilution for existing shareholders.

Key Numbers

• $500K — Gross Proceeds (Raised from the sale of ordinary shares in a private placement.)
• 1,000,000 — Ordinary Shares Sold (Number of shares sold in the private placement at $0.50 per share.)
• 1,000,000 — Warrants Issued (Warrants to purchase ordinary shares at an exercise price of $0.75.)

Key Players & Entities

• TC Biopharm (Holdings) plc (company) — Registrant
• March 12, 2024 (date) — Date of earliest event reported
• $500,000 (dollar_amount) — Gross proceeds from private placement
• 1,000,000 ordinary shares (dollar_amount) — Number of shares sold in private placement
• $0.50 (dollar_amount) — Price per share in private placement
• 1,000,000 ordinary shares (dollar_amount) — Number of shares issuable upon warrant exercise
• $0.75 (dollar_amount) — Exercise price of warrants

FAQ

Key Financial Figures

• $1,263,000 — o the Company of 986,398 (approximately $1,263,000). The warrants were issued by the Compa

Filing Documents

• form8-k.htm (8-K) — 41KB
• 0001493152-24-010194.txt ( ) — 260KB
• tcbp-20240312.xsd (EX-101.SCH) — 4KB
• tcbp-20240312_def.xml (EX-101.DEF) — 26KB
• tcbp-20240312_lab.xml (EX-101.LAB) — 37KB
• tcbp-20240312_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 7KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Maxim 1 , 2 Parklands Way , Holytown , Motherwell , Scotland , United Kingdom ML1 4WR (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: +44 (0) 141 433 7557 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing twenty Ordinary Shares, nominal value 0.0001 per share TCBP The Nasdaq Stock Market LLC Ordinary Shares, nominal value 0.0001 per share* N/A The Nasdaq Stock Market LLC Warrants TCBPW The Nasdaq Stock Market LLC * Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.02 Unregistered Sales of Equity Securities On March 12, 2024, TC Biopharm (Holdings) PLC (the "Company") issued 623,750 american depositary shares (the "ADSs") representing 12,475,000 ordinary shares of the Company upon exercise of outstanding warrants resulting in gross cash proceeds to the Company of 986,398 (approximately $1,263,000). The warrants were issued by the Company on August 30, 2023 as previously disclosed on a Report of Foreign Private Issuer filed with the SEC on August 31, 2023. The Company issued the ADSs pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2024 TC BIOPHARM (HOLDINGS) PLC By: /s/ Martin Thorp Martin Thorp Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR